Aim There is no known specific biomarker or genetic signal for quadruple wild-type (qWT) gastrointestinal stromal tumours (GISTs). By next-generation sequencing (NGS) of different GIST subgroups, this study aimed to characterise such a biomarker especially as a potential therapeutic target.
Methods and results An NGS panel of 672 kinase genes was applied to DNA extracted from 11 wild-type GISTs (including three qWT GISTs) and 5 KIT/PDGFRA mutated GISTs. Short variants which were present in qWT GISTs but no other GIST subgroup were shortlisted. After removing common population variants, in silico-classified deleterious variants were found in CSNK2A1, MERTK, RHEB, ROCK1, PIKFYVE and TRRAP. None of these variants were demonstrated in a separate cohort of four qWT GISTs.
Conclusions Short kinase variants which are specific to qWT GISTs are rare and are not universally demonstrated by this whole subgroup. It is therefore possible that the current definition of qWT GIST still covers a heterogenous population.
- gastrointestinal neoplasms
- molecular biology
Statistics from Altmetric.com
Handling editor Cheok Soon Lee.
Contributors NACSW conceived the idea for the study. NACSW, OTG, RtH and RTC assembled the study cohorts. KR, CF and NACSW performed and/or interpreted the genetic analyses. All authors contributed to the manuscript.
Funding This study was funded by a research grant from GIST Cancer UK.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval This study was approved by the UK National Research Ethics Service (REC reference no: 15/NW/0555).
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.